Ascendia

  MARKET NEWS

Aenova expands its advanced technology portfolio with cutting-edge hot melt extrusion platform
Ofichem acquires Avivia B.V. to expand formulation development capabilities
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
BiomX Announces Successful Initiation of Phase 2b Trial With First Patient Dosed in BX004 Program in Patients With Cystic Fibrosis
PCI Pharma Services Enters Next Phase of Growth With Strategic Investment From Bain Capital, Kohlberg & Mubadala
Vivos Inc. Submitted the Investigational Device Exemption Application for Human Clinical Trials at Mayo Clinic
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
Pelthos Therapeutics Launches ZELSUVMI (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum

  EXPERT CONTENT & RESOURCES

Exploring New Potential Through 505(b)(2)

Exploring New Potential Through 505(b)(2)

When filing for a drug product approval via the 505(b)(2) regulatory pathway rather than a traditional development pathway, companies are afforded several advantages.

Ionizable Lipids in LNPs: A Selection Guide

Ionizable Lipids in LNPs: A Selection Guide

Finding the right ionizable lipid is critical for optimal formulations. This guide helps navigate the wide range of ionizable lipids for specific therapeutic needs. Explore lipids by target or cargo type.

How to Choose the Right CDMO for Your Pharmaceutical Project

How to Choose the Right CDMO for Your Pharmaceutical Project

This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.

  FEATURED EDITORIAL

  COMPANY PROFILE

UPM Pharmaceuticals is a contract development and manufacturing organization (CDMO) with 30+ years of US based experience in development to later-stage clinical and commercial manufacturing of oral solid and semi-solid dosage forms. Beyond our expertise and technology, UPM is a contract manufacturing organization that has a passion for propelling our customers’ journeys from early-stage development to the market, even when the journey doesn’t begin with us. As a large-scale CDMO, technology transfer and scale-up are our specialties; we welcome the opportunity to sit down with you to create a pharma solution by understanding the evolution of your project, your clinical and commercial goals, and how we can work together to get your product across the finish line. Click here for more.

  WHITEPAPERS & WEBINARS

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

Providing Ideal Protection for Invaluable Drug Products, Including Cell and Gene Therapy Products

Product Introduction of OXYCAPT™

OXYCAPT™ is a multilayer plastic vial and syringe, consisting of three layers made from two types of resins.  The drug contact layer and …

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

WHITEPAPER - Container Selection for a Highly Sensitive Drug Product: A Success Story

Our client, a leading pharmaceutical company, came to us for a solution to a very specific problem. They needed a staked needle prefilled syringe (PFS) in a disposable auto-injector for their high-concentration monoclonal antibody product. These products are among the …

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges

Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability are key.

Gattefossé focuses on customers, veterinarians, pet owners, and animals themselves to help them …

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 23 – Transdermal/Topical Delivery

July 30 – TBD